"The Report PharmaPoint:
Psoriatic Arthritis - Global Drug Forecast and Market Analysis to
2025 provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
Psoriatic arthritis (PsA) is a
chronic immune-mediated arthritis typically affecting the large
joints, especially those of the lower extremities and distal joints
of the fingers and toes as well as the back and sacroiliac joints of
the pelvis. In approximately 80% of PsA patients, skin lesions of
psoriasis (PsO), an immune-mediated skin disease, manifest prior to
the development of PsA, typically by five to 10 years. PsA most
commonly develops between the ages of 30 and 50 and affects men and
women equally. Although, early diagnosis and intervention are key in
preventing irreversible joint damage, many PsA patients are
undiagnosed and go untreated for months or years.
GlobalData projects the PsA market
in 7MM to experience strong growth during the forecast period at a
CAGR of 10.74%. By the forecast's end in 2025, sales will increase to
over $12.58 billion from $4.53 billion in 2015. This growth will be
driven primarily by the increase in diagnosed prevalent cases from
1,044,022 in 2015 to 1,520,471 in 2025. Further, the launch of the
IL-17 inhibitors, including Novartis' Cosentyx, Eli Lilly's Taltz,
and AstraZeneca's Lumicef, as well as the launch of Celgene's oral
therapy Otezla, will expand the treatment armamentarium for PsA
driving growth in the market.
View Report @
http://www.marketresearchreports.biz/analysis/990986
Highlights
Key Questions Answered
- How large an impact will
biosimilars have on the PsA market? What do dermatologists,
rheumatologists, and key opinion leaders across the 7MM think about
the evolving treatment landscape?
- What opportunities remain in the
market for new product entrants?
- What are the most promising
late-stage pipeline drugs and how will their launch shape the future
treatment landscape in the PsA market?
- According to KOLs, what are the
most important unmet needs in PsA? Will these needs be addressed by
pipeline agents? What needs will remain by the end of the forecast
period in 2025?
- What clinical and commercial
factors are likely to affect uptake of PsA therapies in the US, 5EU,
and Japan?
Get Sample Copy Of this Report
@
Key Findings
- The PsA market is currently very
dynamic, with effective biologic therapies recently approved,
including interleukin-17 (IL-17) inhibitors - Cosentyx, Taltz, and
Lumicef - and oral phosphodiesterase-4 (PDE4) - Otezla.
- Novel biologic therapies will
challenge the current anti-TNF biologics in an attempt to dislodge
their stronghold, if their safety and efficacy profiles are proven
once they enter the market.
- The impending patent cliff for
biologics will allow for the emergence of biosimilars to all the
marketed biologic brands. Patent expiries take place during the
forecast period for the current market leaders such as Johnson &
Johnsons Remicade (infliximab), AbbVies Humira (adalimumab), Amgens
Enbrel (etanercept) and Johnson & Johnsons Stelara (ustekinumab).
- The drivers for market growth
will include the increasing diagnosis rate as well as the recent
approval of novel therapies. The main challenge for individual drugs
will be to distinguish themselves in a crowded marketplace,
comprising a highly diversified field of therapies, with existing
drugs struggling to increase their patient share.
Scope
- Overview of PsA, including
epidemiology, etiology, pathophysiology, symptoms and
country-specific diagnosis and treatment recommendations.
- Annualized PsA market revenue,
annual cost of therapy and treatment usage pattern data from 2015 and
forecast for ten years to 2025.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, and implications for the PsA market.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, synopses of innovative early-stage projects, and
detailed analysis of novel products- including promising IL-17
inhibitors - and biosimilars - such as Celltrions Hospira, Sandozs
Erelzi, Biogen/Samsung Bioepies Flixabi and Benepali, and Amgens
Amjevita.
- Analysis of the current and
future market competition in the global PsA market (7MM). Insightful
review of the key industry drivers, restraints and challenges. Each
trend is independently researched to provide qualitative analysis of
its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global Psoriasis
market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the Psoriasis market in the
future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the global
PsA market from 2015-2025.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment